Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

HitGen Signs Drug Discovery Deal with Pfizer

publication date: Apr 17, 2017
Chengdu's HitGen entered a multi-year research collaboration and license agreement to build and screen novel DNA-encoded libraries (DELs) with Pfizer. The collaboration aims to discover unique small molecule leads for drug development, though the companies did not disclose any particular disease target. HitGen is on a roll. In the last three months, it has announced three discovery collaborations: Cancer Research UK (lung cancer), Merck/MSD (Merck designated targets), and now Pfizer. More details....

Stock Symbols: (NYSE: PFE) (NYSE: MRK)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital